ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.36 USD
+0.41 (0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.26 -0.10 (-0.15%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIP 65.36 +0.41(0.63%)
Will ANIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Other News for ANIP
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals Financial Report: Key Insights Revealed
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
ANI Pharmaceuticals announces launch of Baclofen Oral Suspension